Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Celcuity's stock experienced a significant decline of over 25% following the release of Phase 3 VIKTORIA-1 data. Despite this drop, the data confirmed the efficacy of gedatolisib, indicating its potential as a leading treatment for advanced breast cancer. Analysts maintain a buy rating, citing the drug's promising results and market potential.
- ▪Celcuity shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's best-in-class efficacy.
- ▪Gedatolisib demonstrated superior progression-free survival and objective response rates compared to current standards.
- ▪The drug is positioned to target a $6 billion market, indicating significant commercial potential.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911391-celcuity-selloff-on-yesterdays-data-unwarranted-buy-rating-upheld"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
